Compare Adaptive Biotechnologies Corp (ADPT) vs Ralph Lauren Corp (RL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Ralph Lauren Corp — how do they compare? Adaptive Biotechnologies Corp trades at $20.03 (market cap $3.33B), while Ralph Lauren Corp trades at $385.9 (market cap $23.53B). The key difference: Ralph Lauren Corp is far larger — about 7.1× Adaptive Biotechnologies Corp's market cap, and Ralph Lauren Corp pays a 0.95% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | RL | |
|---|---|---|
Market Cap | $3.33B | $23.53B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $414.25 |
52-Week Low | $10.24 | $283.34 |
Enterprise Value | $3.19B | $24.47B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Ralph Lauren (RL) trades at $395.31, down 0.73% on the day, with a bullish technical outlook and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.80 surpassing expectations. Revenue growth accelerated to $7.08 billion in 2025, while net income margin improved to 10.49%. Analyst consensus remains strongly bullish with a $446.25 price target, representing 13% upside potential from current levels.
RL presents a compelling growth story with expanding margins and strategic initiatives driving performance. Key risks include consumer discretionary spending sensitivity and competitive pressures in the apparel sector. The company's digital expansion and Next Great Chapter strategy provide catalysts for continued outperformance, though macroeconomic headwinds could impact near-term results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
